Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease. During the past decade, novel pathogenic mechanisms of IPF have been elucidated that have shifted the concept of IPF from an inflammatory-driven to an epithelial-driven disease. Dysregulated repair responses induced by recurrent epithelial cell damage and excessive extracellular matrix accumulation result in pulmonary fibrosis. Although there is currently no curative therapy for IPF, two medications, pirfenidone and nintedanib, have been introduced based on understanding the pathogenesis of the disease. In this review, we discuss advances in understanding IPF pathogenesis, highlighting epithelial–mesenchymal transition (EMT), the ubiquitin-proteasome system, and endothelial cells. TGF-β is a central regulator involved in EMT and pulmonary fibrosis. HECT-, RING finger-, and U-box-type E3 ubiquitin ligases regulate TGF-β-Smad pathway-mediated EMT via the ubiquitin-proteasome pathway. p27 degradation mediated by the SCF-type E3 ligase, Skp2, contributes to the progression of pulmonary fibrosis by promotion of either mesenchymal fibroblast proliferation, EMT, or both. In addition to fibroblasts as key effector cells in myofibroblast differentiation and extracellular matrix deposition, endothelial cells also play a role in the processes of IPF. Endothelial cells can transform into myofibroblasts; therefore, endothelial–mesenchymal transition can be another source of myofibroblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ND L02-s0201 (formerly BMS 986263) is a lipid nanoparticle containing siRNA which inhibits HSP47, which is a collagen specific chaperone that ensures proper collagen formation [190].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [190]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“CDK inhibitors (CKIs) such as p27Kip1 (p27) and p21Cip1 (p21), participate in regulation of the growth and differentiation of both epithelial and interstitial cells in various tissues [107].”
BackgroundSmad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 3×
“Regarding interleukins, levels of the proinflammatory cytokine, IL-18, are elevated in serum, airway epithelium, and alveolar macrophages of patients with IPF [32].”
BackgroundInnate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Cited by
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
“CTGF mediates lung matrix deposition and fibroblast differentiation by activating downstream MAP kinase pathway (Duncan et al., 1999; Inui et al., 2021).”
BackgroundTGF-β signaling: critical nexus of fibrogenesis and cancer
Giarratana, A. O., Prendergast, C. M., Salvatore, M. M., & Capaccione, K. M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05411-4 · Cited by 200
“Currently, there are two Food and Drug Administration (FDA) approved treatments for IPF; pir-fenidone and nintedanib [55].”
BackgroundCigarette Smoke-Induced Respiratory Response: Insights into Cellular Processes and Biomarkers
Cha, S.-R., Jang, J., Park, S., Ryu, S. M., Cho, S.-J., & Yang, S. (2023) · Antioxidants · doi:10.3390/antiox12061210 · Cited by 163
Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases
Yue, Q., Song, Y., Liu, Z., Zhang, L., Yang, L., & Li, J. (2022) · Molecules · doi:10.3390/molecules27154922 · Cited by 130
Ferulic Acid: A Review of Pharmacology, Toxicology, and Therapeutic Effects on Pulmonary Diseases
Zhai, Y., Wang, T., Fu, Y., Yu, T., Ding, Y. P., & Nie, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098011 · Cited by 112
Pulmonary fibrosis: from mechanisms to therapies
Jiang, M., Bu, W., Wang, X., Ruan, J., Shi, W., Yu, S., Huang, L., Xue, P., Tang, J., Zhao, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06514-2 · Cited by 120
“It subsequently recruits and activates circulating fibrocytes and fibroblasts, resulting in ECM production and deposition [130, 131].”
Lou, Y., Zou, X., Pan, Z., Huang, Z., Zheng, S., Xiaowei, Z., Yang, X., Bao, M., Zhang, Y., Gu, J., et al. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae058 · Cited by 69
The effects of epithelial–mesenchymal transitions in COPD induced by cigarette smoke: an update
Su, X., Wu, W., Zhu, Z., Lin, X., & Zeng, Y. (2022) · Respiratory Research · doi:10.1186/s12931-022-02153-z · Cited by 73
Saha, P., & Talwar, P. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04845-6 · Cited by 63
“1) [17].”
The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Xu, Y., Lan, P., & Wang, T. (2023) · Medicina · doi:10.3390/medicina59111984 · Cited by 66
“TGF-β induces epithelial cell damage and apoptosis and directly activates fibroblasts to produce collagen [28].”
BackgroundJi, J., Zheng, S., Liu, Y., Xie, T., Zhu, X., Nie, Y., Shen, Y., & Han, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04279-0 · Cited by 58
“However, it is slightly different from the progression of cancer, in the development of pulmonary fibrosis, when the alveolar epithelial cells are EMT, they are often accompanied by the transformation into fibroblasts [5, 28].”
BackgroundZhang, Y., Liu, Q., Ning, J., Jiang, T., Kang, A., Li, L., Pang, Y., Zhang, B., Huang, X., Wang, Q., et al. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.128655 · Cited by 45
Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis
Zhang, Y., & Wang, J. (2023) · Advances in respiratory medicine · doi:10.3390/arm91010005 · Cited by 53
Diversity of group 1 innate lymphoid cells in human tissues
Jaeger, N., Antonova, A. U., Kreisel, D., Roan, F., Lantelme, E., Ziegler, S. F., Cella, M., & Colonna, M. (2024) · Nature Immunology · doi:10.1038/s41590-024-01885-y · Cited by 50
“ZNF683 + NK cells were also expanded in pulmonary fibrotic tissue, most probably under the influence of hypoxia and TGF-β, which is upregulated in fibrosis 53 .”
The aging lung: microenvironment, mechanisms, and diseases
Wang, Y., Huang, X., Luo, G., Xu, Y., Deng, X., Lin, Y., Wang, Z., Zhou, S., Wang, S., Chen, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383503 · Cited by 66
Injured Endothelial Cell: A Risk Factor for Pulmonary Fibrosis
Zhao, W., Wang, L., Wang, Y., Yuan, H., Zhao, M., Lian, H., Ma, S., Xu, K., Li, Z., & Yu, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108749 · Cited by 47
“TGF-β, as the strongest profibrotic mediator, leads to recruitment and activation of monocytes, circulating fibrocytes, and fibroblasts, and it can be released by alveolar epithelial cells, ECs, macrophages, platelet granules, and infiltrating regulatory T cells [59].”
BackgroundMesenchymal cells in the Lung: Evolving concepts and their role in fibrosis
Ligresti, G., Raslan, A., Hong, J., Caporarello, N., Confalonieri, M., & Huang, S. K. (2023) · Gene · doi:10.1016/j.gene.2022.147142 · Cited by 43
Natural plant resource flavonoids as potential therapeutic drugs for pulmonary fibrosis
Wang, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19308 · Cited by 36
Tu, J., Chen, X., Li, C., Liu, C., Huang, Y., Wang, X., Liang, H., & Yuan, X. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92620 · Cited by 42
“TGF-β1 is a key mediator of the differentiation of fibroblasts into pro-fibrotic myofibroblasts [64, 66].”
BackgroundMammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond
Lillehoj, E. P., Luzina, I. G., & Atamas, S. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883079 · Cited by 37
Ba, X., Wang, H., Huang, Y., Yan, J., Han, L., Lin, W., Shen, P., Huang, Y., Yang, S., Qin, K., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116274 · Cited by 35
Liu, B., Li, F., Wang, Y.-X., Gao, X., Li, Y., Wang, Y., & Zhou, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437113 · Cited by 46
Cai, Y., Jiang, S., Huang, C., Shen, A., Zhang, X., Yang, W., Xiao, Y., Gao, S., Du, R., Zheng, G., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154747 · Cited by 31
Liu, H., Lai, W., Nie, H., Shi, Y., Zhu, L., Yang, L., Tian, L., Li, K., Bian, L., Xi, Z., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.108290 · Cited by 33
Qi, J., Wu, Y., Guo, Z., Zhu, S., Xiong, J., Hu, F., Liang, X., & Ye, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132896 · Cited by 34
Nets in fibrosis: Bridging innate immunity and tissue remodeling
Ma, X., Ji-pin, L., Li, M., Qi, G., Wei, L., & Zhang, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112516 · Cited by 33
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
Notch signaling regulates pulmonary fibrosis
Zhang, X., Xu, Z., Chen, Q., & Zhou, Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1450038 · Cited by 35
Li, N., Qiu, L., Zeng, C., Fang, Z., Chen, S., Song, X., Song, H., & Zhang, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4224 · Cited by 31
“Dysregulated repair responses induced by recurrent epithelial cell damage and excessive extracellular matrix accumulation result in pulmonary fibrosis (3).”
BackgroundStem cell-based therapy for fibrotic diseases: mechanisms and pathways
Taherian, M., Bayati, P., & Mojtabavi, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03782-5 · Cited by 39
“Two new FDA-approved anti-fibrotic agents, pir-fenidone and nintedanib, retarded disease progression in phase III studies, however, did not improve survival and quality of life [192].”
BackgroundHussein, Z. A., Abu-Raghif, A. R., & Fawzi, H. A. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14018 · Cited by 29
Relationship between asporin and extracellular matrix behavior: A literature review
Fan, R., Yan, X., & Zhang, W. (2022) · Medicine · doi:10.1097/md.0000000000032490 · Cited by 30
“[10,11] To exemplify, EMT mediated pulmonary fibrosis (PF),[12] cardiac repair postmyocardial infarction,[13] osteoarthritis (OA),[1] rheumatoid arthritis,[14] ovarian tumor growth,[15] keloid disorders,[16] and beyond.”
BackgroundCussonneau, L., Boyer, C., Brun, C., Deval, C., Loizon, E., Meugnier, E., Guéret, É., Dubois, E., Taillandier, D., Polge, C., et al. (2021) · Cells · doi:10.3390/cells10081873 · Cited by 29
“transcripts involved in TGF-β and BMP signaling pathways and depicting (i) their relationships [12,60] and (ii) the difference”
Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition
Pi, P., Zeng, Z., Zeng, L., Han, B., Bai, X., & Xu, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1218059 · Cited by 31
“EMT is a dynamic and reversible transdifferentiation process in which epithelial cells lose part of their epithelial cell characteristics and acquire the typical characteristics of mesenchymal cells (Inui et al., 2021).”
BackgroundLi, W., Xie, Y., Chen, Z., Cao, D., & Wang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1658001 · Cited by 43
Qi, J., Zhang, X., Zhang, S., Wu, S., Lu, Y., Li, S., Li, P., & Tan, J. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02070-3 · Cited by 32
“Dysregulation of ubiquitin-mediated protein degradation can cause a variety of diseases, including cancer, neurodegenerative diseases, and tissue fibrosis [26].”
BackgroundSehgal, M., Jakhete, S. M., Manekar, A. G., & Sasikumar, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09773 · Cited by 24
Tan, J., Xue, Q., Hu, X., & Yang, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04884-7 · Cited by 24
“However, studies have shown that transforming growth factor (TGF)-β signaling plays a central role in fibrosis progression [8].”
BackgroundZhang, J., Chen, W., Du, J., Chu, L., Zhou, Z., Zhong, W., Liu, D., Huang, H., Huang, Y., Qiao, Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109985 · Cited by 22
Shi, X., Pan, Z., Cai, W., Zhang, Y., Duo, J., Liu, R., & Cai, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1171445 · Cited by 20
The emerging roles of SUMOylation in pulmonary diseases
Zheng, X., Wang, L., Zhang, Z., & Tang, H. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00719-1 · Cited by 26
“SUMO-1 inhibitor GA may reduce SUMOylation activity by upregulating SENP1 and thereby prevent the development of IPF(Yu et al. 2022).”
BackgroundInfluentialAkahori, D., Inui, N., Inoue, Y., Yasui, H., Hozumi, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168996 · Cited by 20
Self-citationEmerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
“SMURF1 and SMURF2 promote ubiquitin-dependent degradation of Smad7 and enhancement of TGF-β, which contributes to pulmonary fibrosis [190].”
Ginkgolic acid improves bleomycin‐induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation
Yu, L., Bian, X., Zhang, C., Wu, Z., Huang, N., Yang, J., Jin, W., Feng, Z., Li, D., Huo, X., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8002566 · Cited by 19
“Additionally, recent studies have shown that SMAD4 participates in PF through its nuclear localization and by promoting epithelial-mesenchymal transition (EMT) [32, 34].”
Lu, J., Wang, Z., & Zhang, L. (2025) · Gene · doi:10.1016/j.gene.2025.149271 · Cited by 21
Anthelmintic nitazoxanide protects against experimental pulmonary fibrosis
Chen, X., Dong, Y., Yu, Y., Jiang, M., Bu, W., Li, P., Sun, Z., & Dong, D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16190 · Cited by 17
“Activated Smad2/3 signal is critical in TGF-β -mediated EMT (Inui et al., 2021).”
BackgroundPirfenidone and nintedanib attenuate pulmonary fibrosis in mice by inhibiting the expression of JAK2
Yang, Y., Wang, X., & Zhang, J. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1057 · Cited by 21
“Furthermore, TGF-β 1 signaling induces fibrosis not only through Smad-dependent canonical pathways but also through Smad-independent noncanonical pathways, such as the JAK/STAT, Ras-MAPK, TAK1-p38/ JNK, PI3K-Akt, and Par6-Smurf1 pathways (14,15).”
Wang, J., Xia, Z., Qing, B., Chen, Y., Gu, L., Chen, H., Ge, Z., & Yuan, Y. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00983-9 · Cited by 17
Molecular mechanisms and emerging therapeutics in pulmonary fibrosis: A recent update
Sharma, P. L., Kumari, K., Yadav, R., Verma, K., Paliwal, S., Paliwal, S., & Sharma, S. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178159 · Cited by 17
Ferreira, R. R., de Souza, E. M., Vilar-Pereira, G., Degrave, W., Abreu, R. D. S., Meuser-Batista, M., Ferreira, N. V. C., Ledbeter, S., Barker, R. H., Bailly, S., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1017040 · Cited by 15
“…Okada et al., 2005; Tan et al., 2010; Bhandary et al., 2018; Frangogiannis, 2020; Ko et al., 2022) and in other organs such as kidney, liver and lung (Daniels et al., 2004; Wang et al., 2005; Gellibert et al., 2006; Petersen et al., 2008; Dewidar et al., 2019; Gu et al., 2020; Inui et al., 2021).”
BackgroundMolecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19
Kooistra, E. J., Dahm, K., van Herwaarden, A. E., Gerretsen, J., Nuesch-Germano, M., Mauer, K., Smeets, R. L., van der Velde, S., van den Berg, M. J. W., van der Hoeven, J. G., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02496-1 · Cited by 18
Xiao, T., Gao, D., Gu, X., Zhang, Y., Zhu, Y., Zhang, Z., He, Y., Wei, L., Li, H., Zhou, H., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175981 · Cited by 16
Liao, Y., Peng, X., Yang, Y., Zhou, G., Chen, L., Yang, Y., Li, H., Chen, X., Guo, S., Zuo, Q., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2409352 · Cited by 15
“…fibrosis [58]. tGF-β is crucial in fibrosis, promoting fibroblast activity and collagen deposition, and creating a cycle that exacerbates fibrosis [59]. however, some studies show different results; for instance, bosutinib increased M2 macrophages but resisted fibrosis [60]. and human mesenchymal…”
ResultZhang, Y., Qi, C., Wei, Q., Li, Y., & Tian, P. (2025) · Respiratory Research · doi:10.1186/s12931-025-03294-7 · Cited by 17
“…mediators, which undergo pathological remodeling and aberrant cross-linking, thereby altering the mechanical properties of the cellular extracellular matrix and leading to irreversible structural changes and tissue sclerosis in the lungs, thus creating a procan-cer microenvironment [55].”
Lee, J. H., Jang, J. H., Lee, S., & Her, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412126 · Cited by 17
Transforming Growth Factor‐β Pathway: Biological Functions and Therapeutic Targets
Mekky, R. H., Fetoh, M. E. A., Faheem, S. A., Radwan, A., Fawzy, M. H., Mustafa, A. M., Said, M. A., Călina, D. C., Sharifi‐Rad, J., & Cho, W. C. S. (2025) · MedComm · doi:10.1002/mco2.70278 · Cited by 17
“In pulmonary fibrosis, TGF-β promotes fibroblast activation, EMT, and ECM deposition, resulting in irreversible architectural damage; these effects can be attenuated by agents that inhibit mitochondrion-mediated oxidative stress [16–18].”
Rispoli, P., Piovesan, T. S., Decorti, G., Stocco, G., & Lucafò, M. (2023) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1630 · Cited by 17
Wen, Z., & Ablimit, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-70659-1 · Cited by 12
Zhu, D., Zhang, Q., Li, Q., Wang, G., & Guo, Z. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3442 · Cited by 12
“TGF-β1 is the most prevalent subtype.(26) Smad3 participates in TGF-β1 signal transduction and plays a key role in IPF progression.”
BackgroundLi, X., Li, W., Zhang, Y., Xu, L., & Song, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101150 · Cited by 12
Pan, J., Li, Y., Wu, X., Pan, X., Liu, C., Zhang, H., Wang, L., Jiang, X., Wang, J., Zang, N., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117507 · Cited by 10
Ding, C., Liu, B., Yu, T., Wang, Z., Peng, J., Gu, Y., & Li, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117477 · Cited by 13
Protein Ubiquitination Modification in Pulmonary Fibrosis
Shen, J., Jiang, Y., Bu, W., Yu, M., Huang, R., Tang, C., Yang, Z., Gao, H., Su, L., Cheng, D., et al. (2025) · Comprehensive physiology · doi:10.1002/cph4.70013 · Cited by 11
“SMAD proteins, as primary transcription factors in the TGF-β pathway, directly impact gene expression in stromal cells, promoting their differentiation into fibroblasts (Inui et al. 2021).”
InfluentialCui, E., Zhang, L., Pan, X., Zhang, Q., Zhang, L., Wu, F., Chen, N., Lv, L., Chen, W., Chen, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1021102 · Cited by 12
“Some studies (38, 39) have suggested that excessive accumulation of ECM contributes to pulmonary fibrosis.”
BackgroundRegulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
Tseng, Y., Chen, I., Li, W., & Hsu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310876 · Cited by 10
“As the etiology of ILD remained unclear [4], it is believed that fibrosis is a common pathological feature in many chronic inflammatory diseases [5].”
BackgroundFang, H., Zheng, H., Jiaqi, W., Dong, T., Yiyuanzi, Z., Qiwen, Y., Ying, L., Hongchun, Z., & Liu, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1258885 · Cited by 11
Potential saviour of pulmonary fibrosis: multi-pathway treatment of natural products
Weng, Y., He, B., Zhou, J., Luo, P., Xu, Z., Yan, H., Yang, B., He, Q., Lu, J., & Yang, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157174 · Cited by 10
Sun, M., Zhang, F., Lu, F., Yu, D., Wang, Y. T., Chen, P., & Liu, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1358626 · Cited by 12
“…epithelial cell injury would cause abnormal activation of epithelial cells and then secrete a large amount of transforming growth factor-β (TGF-β ) (Inui et al., 2021), which was characterized by interstitial scar formation and irreversible decline in lung function (Strykowski and Adegunsoye,…”
BackgroundLiu, M., Liu, H., Kang, H., Wu, J., Xing, P., Ding, X., Wei, Y., & Kong, X. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117534 · Cited by 9
Molecular mechanisms of postintensive care syndrome
Martín-Vicente, P., López‐Martínez, C., López-Alonso, I., López‐Aguilar, J., Albaiceta, G. M., & Amado‐Rodríguez, L. (2021) · Intensive Care Medicine Experimental · doi:10.1186/s40635-021-00423-6 · Cited by 10
“During EMT, epithelial cells lose part of the epithelial characteristics, such as expression of E-cadherin and cytokeratin, and gain mesenchymal markers including N-cadherin, vimentin or α-smooth muscle actin [24].”
BackgroundLang, C., Huang, B., Chen, Y., & He, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1615991 · Cited by 11
Toosendanin Restrains Idiopathic Pulmonary Fibrosis by Inhibiting ZEB1/CTBP1 Interaction
Li, X.-B., Bai, Z., Li, Z., Wang, J., & Yan, X. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230501205149 · Cited by 8
“By binding to the corresponding receptors, they stimulate the proliferation of fibroblasts and induce their transformation into MB [30].”
BackgroundExamining the contribution of Notch signaling to lung disease development
Antar, S. A., ElMahdy, M. K., & Darwish, A. G. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03105-8 · Cited by 9
“As such, pharmacological interventions targeting this signaling pathway could represent a promising approach for managing chronic fibroproliferative conditions and widespread tissue fibrosis (Inui et al. 2021).”
Identification and functional analysis of a three-miRNA ceRNA network in hypertrophic scars
Zhang, Z., Huang, X., Yang, J., Gu, S., Zhao, Y., Liu, Y., Khoong, Y., Wang, S., Luo, S., Zan, T., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03091-y · Cited by 8
Zhang, Y., Xia, Y., Zhang, R., Zhou, X., & Jiang, J. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.05.015 · Cited by 7
The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
Monteleone, G., Cameli, P., & Bonella, F. (2025) · European Respiratory Review · doi:10.1183/16000617.0147-2024 · Cited by 10
Liu, R., Wu, T., Zhou, W., Zhu, A., Liao, W., & Ding, K. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c11703 · Cited by 10
Lysosomal Acidification: A New Perspective on the Pathogenesis and Treatment of Pulmonary Fibrosis
Tian, K., Yu, M., Jiang, M., Gao, Z., Zheng, D., Shi, W., Cheng, D., & Zhao, X. (2025) · Comprehensive physiology · doi:10.1002/cph4.70023 · Cited by 8
“…plays a similarly crucial role in the kidney; during chronic inflammation, renal tubulointer-stitial cells transdifferentiate into myofibroblasts under TGF-β stimulation, depositing collagen and representing a major mechanism of renal fibrosis (Inui et al. 2021; Zhou et al. 2020; Fei et al. 2024).”
Wu, W., Wang, Z., Zhang, H., Zhang, X., & Tian, H. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09839-8 · Cited by 7
“In both in vivo and in vitro models of IPF, overactivated TGF-β1 signal is the central regulator of abnormal EMT progression of LECs (Inui et al. 2021; Andugulapati et al. 2020).”
Elliot, S. J., Anderson-Bell, D., Roos, B. B., Rubio, G. A., Xia, X., Pereira‐Simon, S., Catanuto, P., Civettini, G., Hagen, E. S., Arvanitis, C., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102461 · Cited by 6
“17,18 The dysregulation of ECM turnover linked to activation of the AKT and TGF-b signaling pathways, is a key driver of fi brosis in IPF 24,56 and BLM models.”
He, J., Yue, H., Zhang, S., Dong, R., Zhang, F., Wang, X., Wang, K., Zhang, H., Yang, D., Dong, Z., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03218-5 · Cited by 6
“TGF-β1, recognized as the initiating hub in the formation and development of PF, can activate both SMAD and non-SMAD signaling pathways [53, 54].”
Immunobiology of pulmonary fibrosis
Bindu, S., Yasmin, H., Barman, U., Pandit, S., Masmoudi, K., & Kishore, U. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708716 · Cited by 7
Liu, S., He, Y., Li, S., Gao, X., & Yang, F. (2023) · Science Progress · doi:10.1177/00368504221148340 · Cited by 7
“During silicosis, epithelial cells undergo an epithelial-myofibroblast transition (EMyT), a source of myofibroblasts characterized by the positive expression of α-smooth muscle actin (α-SMA) and collagen deposition.(50,51) KIF3A serves as a subunit of the microtubular motor and exerts a suppressive effect on EMyT.”
BackgroundLiu, X., Huang, Y., Zhao, X., Guan, Y., Li, Y., Yuan, L., Wang, C., Ma, C., & Ma, E. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107961 · Cited by 6
Wei, Y., Jia, Z., Ma, J., Zhang, W., Li, H. Y., Wu, J., Wang, X., Yu, X., Shi, Y., Kong, X., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00715 · Cited by 7
Nanodrug delivery system for precision treatment of pulmonary fibrosis
Yi, X., Zhang, X., Guan, Y., Sha, Y., Cheng, X., Lee, Y. C., & Yuan, W. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100025 · Cited by 8
Yang, C., Qin, Z., Ma, H., Liu, H., Hou, M., Wei, J., Guo, H., An, X., Yang, F., Yang, A., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123696 · Cited by 5
Alanazi, I. M., Nahas, H. H. A., Mohamed, D. I., Hosny, N., Elewa, Y. H. A., Agarwal, M., Ibrahim, I. A. A., Falemban, A. H., Bamagous, G. A., Sindi, E. R., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18121820 · Cited by 6
From Fibrosis to Malignancy: Mechanistic Intersections Driving Lung Cancer Progression
Chen, B., Hamdy, H., Zhang, X., Cao, P., Fu, Y., & Shen, J. (2025) · Cancers · doi:10.3390/cancers17233861 · Cited by 6
“PF myofibroblasts originate from diverse sources, including mesenchymal progenitor cells, resident lung fibroblasts, AECs undergoing EMT, and bone marrow-derived fibrocytes [15] and endothelial cells [16].”
Cucinotta, L., Mannino, D., Casili, G., Repici, A., Crupi, L., Paterniti, I., Esposito, E., & Campolo, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02519-x · Cited by 8
Mu, S., Xu, R., Wu, X., Cheng, Y., Sun, Z., Liu, H., Shao, H., Zhang, X., Zhang, X., Yang, M., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70043 · Cited by 6
“…factors and extracellular matrix (ECM) deposition, leads to mesenchymal cell activation/proliferation, epithelial – mesenchymal transition (EMT) and transformation of fibroblasts to myofibroblasts, culminating in parenchymal destruction (Hill et al., 2019; Inui et al., 2021; Moss et al., 2022).”
A multidisciplinary approach towards modeling of a virtual human lung
Lam, T., Quach, H. T., Hall, L., Chakra, M. A., & Wong, A. P. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00517-x · Cited by 7
“Many of these pathways are disrupted in disease or activated as part of the body ’ s response to it, necessitating an in-depth investigation into the complex cellular interactions, regulatory networks, and their downstream effects 5,6 .”
Wang, X., Liu, C., Li, X., Guo, K., Xu, S., Zhou, J., Wang, S., Wu, X., Yan, G., & Cui, H. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115727 · Cited by 5
Small Leucine Rich Proteoglycan in Fibrotic Diseases: New Frenemies?
Guo, J., Wang, Y., Liang, H., & Yang, B. (2023) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2023.100005 · Cited by 5
Gao, Z.-Y., Xu, M.-Z., Liu, C., Gong, K., Yu, X., Lu, K., Zhu, J., Guan, H., & Zhu, Q. (2024) · Pharmaceuticals · doi:10.3390/ph17050584 · Cited by 5
“One of them, a type 2 EMT, is caused by persistent injury and inflammation, and is an important process of organ fibrosis [8].”
BackgroundJiang, Y., Zhao, Q., Zhang, T., Lan, S., Yan, X., & Chen, Q. (2025) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-025-01060-z · Cited by 6
“TGF-β is a central regulator of EMT and may affect the EndMT of lung endothelial cells in pulmonary fibrosis (Inui et al .”
Inhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities
Gao, X., Li, X., Zhang, C., Zhou, J., Gu, K., Liu, X., & Bai, C. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157048 · Cited by 4
Qian, R., Xu, Y., Zhang, L., Wang, L., Chen, X., Yao, Y., & Xie, L. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120757 · Cited by 4
Yuan, S., Zhu, W., Wang, Y., & Yu, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s539571 · Cited by 6
“56 In addition, TGFβ is involved in the immunoregulation of fibrosis by regulating the function of immune cells, such as macrophages and T cells.”
Sun, Y., Xu, H., Lu, T., Li, T., Wang, Y., Fan, X., Jiang, Y., Cai, M., He, P., & Liu, J. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01182-9 · Cited by 5
“TGF-β secreted by M2 macrophages is the primary mediator for the induction of PF and is involved in the dynamic pathophysiology of IPF [45] (Fig.”
Background
Metadata
- Authors
- Inui, N., Sakai, S., & Kitagawa, M.
- Affiliations
- Hamamatsu University (JP)
- Corresponding author
- Inui, Naoki
- Kitagawa, Masatoshi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-05
- Volume
- 22
- Issue
- 11
- Pages
- 6107
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8201174
- OpenAlex
- W3169709719
- Cited by
- 169
- References
- 119
- Citations by year
- 2026: 25 · 2025: 52 · 2024: 31 · 2023: 43 · 2022: 14 · 2021: 4
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (20K08539)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, TGF-beta signaling, ubiquitin-proteasome system, epithelial-mesenchymal transition, endothelial-to-mesenchymal transition, E3 ubiquitin ligase, p27 degradation, Skp2, myofibroblast differentiation, extracellular matrix deposition, interstitial lung disease, pirfenidone, nintedanib, fibroblast proliferation
- MeSH terms
- Humans, Pulmonary Fibrosis, Signal Transduction, Transforming Growth Factor beta, Proliferating Cell Nuclear Antigen, Ubiquitin, S-Phase Kinase-Associated Proteins, Proteasome Endopeptidase Complex, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.